The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Horsepower may be the automotive industry’s most important metric. Typically, horsepower is the first spec listed on a manufacturer’s website, the first number people look at, and the figure that ...

Artificial Intelligence (AI) has achieved remarkable successes in recent years. It can defeat human champions in games like Go, predict protein structures with high accuracy, and perform complex tasks ...

If only they were robotic! Instead, chatbots have developed a distinctive — and grating — voice. Credit...Illustration by Giacomo Gambineri Supported by By Sam Kriss In the quiet hum of our digital ...

As language models (LMs) improve at tasks like image generation, trivia questions, and simple math, you might think that human-like reasoning is ...

Artificial intelligence has become almost impossible to avoid, and for many, it's slowly replacing Google and other search engines. But while ChatGPT and its competitors can be useful, it's important ...